NeuroFrontiers
Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health.
So if you want to stay up to date on the latest clinical research and news on neurological disorders, then look no further. Because NeuroFrontiers is where neurology specialists and great minds explore the mind itself.
31-45 of 381
How Real-World Adherence Is Shaping Preventive Migraine Treatment
NeuroFrontiersHow Real-World Adherence Is Shaping Preventive Migraine Treatment
Alexandria May, PharmD, BCPS
Jessica Ailani, MD, FAHS, FAAN, FANA
Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols
NeuroFrontiersRecognizing TK2d: Key Clinical Signs and Diagnostic Protocols
Alexandria May, PharmD, BCPS
Kaitlin Batley, MD
Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
NeuroFrontiersIdentifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
Charles Turck, PharmD, BCPS, BCCCP
Bethany Lussier, MD
Understanding Variability in Myasthenia Gravis
NeuroFrontiersUnderstanding Variability in Myasthenia Gravis
Henry Kaminski, MD
Examining the Global Genetic Prevalence of TK2d
NeuroFrontiersExamining the Global Genetic Prevalence of TK2d
Brian P. McDonough, MD, FAAFP
Austin Larson, MD
Microglia Drive Neurodegeneration in Friedreich’s Ataxia
NeuroFrontiersMicroglia Drive Neurodegeneration in Friedreich’s Ataxia
Ryan Quigley
- advertisement
MS in Women: How Life Stages Shape Treatment Decisions
NeuroFrontiersMS in Women: How Life Stages Shape Treatment Decisions
Is Friedreich’s Ataxia Developmental or Degenerative?
NeuroFrontiersIs Friedreich’s Ataxia Developmental or Degenerative?
Arnulf Koeppen, MD
Unpacking the Genetics of Friedreich’s Ataxia
NeuroFrontiersUnpacking the Genetics of Friedreich’s Ataxia
Arnulf Koeppen, MD
Friedreich’s Ataxia: Impact of Frataxin Loss
NeuroFrontiersFriedreich’s Ataxia: Impact of Frataxin Loss
Arnulf Koeppen, MD
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
NeuroFrontiersSPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
BCMA mRNA CAR-T Shows Durable Benefit in MG
NeuroFrontiersBCMA mRNA CAR-T Shows Durable Benefit in MG
- advertisement
Next-Generation MS Care: The Promise of Cell-Based Therapeutics
NeuroFrontiersNext-Generation MS Care: The Promise of Cell-Based Therapeutics
Mark Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
NeuroFrontiersRAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
Mark Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC
